In an effort to supercharge distribution of its vaccine hopeful, British drugmaker AstraZeneca has spanned the globe to ink a slew of national supply deals. Now, after striking a more limited pact in June, AstraZeneca and Brazil are ramping up their partnership to make even more doses of the shot.

Brazilian President Jair Bolsonaro ordered $360 million set aside last week for a supply and licensing deal with AstraZeneca for at least 100 million doses of the University of Oxford's adenovirus-based COVID-19 vaccine.

Those funds will cover the initial 100 million-dose order, AstraZeneca said, as well as Brazil's licensing rights to produce the shot at the Oswaldo Cruz Foundation, also known as Fiocruz, if the vaccine is found effective in clinical trials.

An AstraZeneca spokesman said the new agreement "builds on" the drugmaker's earlier deal with Brazil in June to supply around 30 million unfinished doses of the vaccine at a price tag of $127 million.

RELATED: AstraZeneca reaches supply deal with Brazilian government to produce millions of doses of COVID-19 shot

In that initial pact, which AstraZeneca described as a "letter of intent," Brazil agreed to make available around 30 million finished doses of the vaccine, with roughly half that haul available by December.

Brazil also committed to produce an additional 70 million doses, with AstraZeneca supplying the unfinished vaccine at no cost.

The vaccine doses were set to be finished and filled at Fiocruz as AstraZeneca does not have a vaccine production suite at its Brazilian manufacturing facility.

RELATED: AstraZeneca taps JCR Pharmaceuticals, Daiichi Sankyo and other local pharmas to supply COVID-19 shots to Japan

The expanded Brazil deal comes as AstraZeneca looks to lock up manufacturing capacity to reach its stated goal of 2 billion doses produced annually.

Last week, Japan agreed to buy 120 million doses the Oxford vaccine, Reuters reported, quoting the country's health minister, Katsunobu Kato. Should the shot cross the regulatory finish line, AstraZeneca will begin deployment to Japan next year, with an initial 30 million doses expected by March.

In tandem, AstraZeneca reached a licensing deal with Chinese firm BioKangtai to provide the shot to China. The pair will also explore the possibility of producing the vaccine for other markets.